Abstract

The pooled cohort equations (PCE) predict atherosclerotic cardiovascular disease (ASCVD) risk in patients with characteristics within prespecified ranges and has uncertain performance among Asians or Hispanics. It is unknown if machine learning (ML) models can improve ASCVD risk prediction across broader diverse, real-world populations. We developed ML models for ASCVD risk prediction for multi-ethnic patients using an electronic health record (EHR) database from Northern California. Our cohort included patients aged 18 years or older with no prior CVD and not on statins at baseline (n = 262,923), stratified by PCE-eligible (n = 131,721) or PCE-ineligible patients based on missing or out-of-range variables. We trained ML models [logistic regression with L2 penalty and L1 lasso penalty, random forest, gradient boosting machine (GBM), extreme gradient boosting] and determined 5-year ASCVD risk prediction, including with and without incorporation of additional EHR variables, and in Asian and Hispanic subgroups. A total of 4309 patients had ASCVD events, with 2077 in PCE-ineligible patients. GBM performance in the full cohort, including PCE-ineligible patients (area under receiver-operating characteristic curve (AUC) 0.835, 95% confidence interval (CI): 0.825–0.846), was significantly better than that of the PCE in the PCE-eligible cohort (AUC 0.775, 95% CI: 0.755–0.794). Among patients aged 40–79, GBM performed similarly before (AUC 0.784, 95% CI: 0.759–0.808) and after (AUC 0.790, 95% CI: 0.765–0.814) incorporating additional EHR data. Overall, ML models achieved comparable or improved performance compared to the PCE while allowing risk discrimination in a larger group of patients including PCE-ineligible patients. EHR-trained ML models may help bridge important gaps in ASCVD risk prediction.

Highlights

  • Risk assessment algorithms have a well-established role in guiding atherosclerotic cardiovascular disease (ASCVD) management

  • N number, ASCVD atherosclerotic cardiovascular disease, CVD cardiovascular disease, pooled cohort equations (PCE) pooled cohort equation, highdensity lipoprotein (HDL)-C high-density lipoprotein cholesterol, BP blood pressure. *Patients with an outcome event within the 5-year follow-up window were not excluded. †Pre-existing cardiovascular disease was defined by International Classification of Diseases, 9th revision, Clinical Modification (ICD-9CM) codes, including: atrial fibrillation: 427.31; heart failure: 428*; coronary artery disease: 411*, 413*, 414*; myocardial infarction: 410*; and stroke: 430–434*, 436*

  • We found that incorporating structured electronic health record (EHR) data beyond PCE variables did not substantially improve machine learning (ML) model risk

Read more

Summary

Introduction

Risk assessment algorithms have a well-established role in guiding atherosclerotic cardiovascular disease (ASCVD) management. The 2018 update to the 2013 ACC/AHA prevention guidelines highlighted the use of the revised pooled cohort equations (PCE) to determine ASCVD risk, which is used to guide crucial management decisions, the initiation of moderate to high-intensity statin therapy for long-term risk reduction[1]. Developed using Cox proportional hazards modeling, the PCE represent a widely used guideline-endorsed calculator to assess 10-year ASCVD event risk for individuals without a prior history of ASCVD, and are a central part of ASCVD risk reduction approaches in clinical settings[2]. PCE use is limited for patients with values outside the prespecified PCE ranges as well as patients without all variables available, preventing accurate guideline-based risk estimation to guide ASCVD risk reduction strategies. The ACC/AHA Work Group that developed the PCE noted that the risk estimator may not accurately predict risk in other racial/ethnic groups[4]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call